Scientists Find the Body's Natural “Off Switch” That Shuts Down Inflammation

Inflammation protects us — until it doesn't switch off. Researchers at University College London have now mapped a natural braking system that the body uses to bring inflammation to an end, opening a route to safer anti-inflammatory treatments.

1.Why an “off switch” matters

Inflammation is one of the immune system's most essential defenses. It helps the body fight infection and repair damaged tissue. But if that response stays switched on too long, it begins to harm healthy tissue — and it contributes to conditions including arthritis, heart disease, and diabetes.

Scientists have long understood a great deal about how inflammation begins. What has been far less clear is how the body decides the danger has passed, and shifts from fighting a threat to repairing the damage. That missing "resolution" step is exactly where this new research lands.

2.What the study did — entirely in humans

The study, published in Nature Communications, points to a group of small fat-derived molecules called epoxy-oxylipins as part of the body's shutdown process. These molecules act like natural brakes on the immune system — helping to prevent excessive growth of intermediate monocytes, a type of white blood cell that supports healing in the short term but can drive chronic inflammation if too many accumulate or stay active too long.

Unlike much immunology work done in mice, this was a controlled experiment in healthy human volunteers. Participants received a tiny injection of UV-killed E. coli bacteria in the forearm. Because the bacteria were dead, they couldn't cause an infection — but they still triggered a temporary inflammatory response with the familiar signs of pain, redness, heat, and swelling.

Volunteers were split into two arms. In the prophylactic arm (24 people), the drug was given two hours before inflammation began. In the therapeutic arm (another 24 people), it was given four hours after inflammation had started — closer to how a real treatment would be used once symptoms appear. The drug used, GSK2256294, blocks an enzyme called soluble epoxide hydrolase (sEH). Because sEH normally breaks down epoxy-oxylipins, blocking it lets more of these protective molecules remain in the body.

3.Pain resolved faster, harmful cells fell

Both approaches produced similar results.

Interestingly, the drug did not significantly change the outward signs of redness or swelling. That suggests it was altering deeper immune processes even while visible symptoms stayed largely unchanged — a subtlety that matters: it wasn't merely masking symptoms, but reshaping the immune response beneath the surface.

4.The mechanism: a brake on the immune system

Digging into the molecular level, the team found that one specific epoxy-oxylipin — 12,13-EpOME — appears to suppress a signaling pathway known as p38 MAPK. This pathway helps drive the transformation of monocytes into the "intermediate" form associated with prolonged inflammatory activity. They confirmed the mechanism in laboratory experiments and in volunteers who received a drug that directly blocks p38.

"Our findings reveal a natural pathway that limits harmful immune cell expansion and helps calm inflammation more quickly." — first author Dr. Olivia Bracken, UCL

5.Why this points to safer treatments

This is the part with real clinical potential. Many existing treatments for inflammatory and autoimmune disease work by suppressing parts of the immune system — which reduces inflammation, but can also leave people more vulnerable to infection. The pathway identified here offers a different strategy: strengthening a natural process the body already uses to bring inflammation under control.

Corresponding author Professor Derek Gilroy (UCL Division of Medicine) put it plainly: "This is the first study to map epoxy-oxylipin activity in humans during inflammation. By boosting these protective fat molecules, we could design safer treatments for diseases driven by chronic inflammation." Because the drug tested is already suitable for human use, it could potentially be repurposed to treat flares in chronic inflammatory conditions — an area, he notes, "currently bereft of effective therapies."

6.The link to aging and "inflammaging"

For anyone interested in longevity, the relevance runs deep. Chronic, low-grade inflammation that rises with age — often called "inflammaging" — is one of the best-established hallmarks of aging, linked to frailty, cardiovascular disease, metabolic decline, and neurodegeneration. A clearer understanding of how the body normally resolves inflammation gets us closer to intervening in that process.

7.What it doesn't prove yet